|
Cangrelor (trade name Kengreal in the US and Kengrexal in Europe) is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation.〔 Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring ()] conversion. Poor interim results led to the abandonment of the two CHAMPION clinical trials in mid-2009.〔(CHAMPION Trials With Cangrelor Stopped for Lack of Efficacy )〕 The BRIDGE study, for short term use prior to surgery, continues.〔(What Cangrelor Failure Means to Medicines )〕 The CHAMPION PHOENIX trial was a randomized study of over 11,000 patients published in 2013. It found usefulness of cangrelor in patients getting cardiac stents. Compared with clopidogrel given around the time of stenting, intravenous ADP-receptor blockade with cangrelor significantly reduced the rate of stent thrombosis and myocardial infarction.〔Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events (2013) Bhatt, DL etal. New England Journal of Medicine March 10, 2013 (published initially online).〕 Reviewers have questioned the methodology of the trial. ==Medical use== According to recent phase 3 randomized trials, a cangrelor–clopidogrel combination is safe and has been found to be more effective than standard clopidogrel treatment at reducing ischemic events in the heart, without increasing major bleeding in the treatment of stenotic coronary arteries.〔 The advantages of this drug combination are most prominent in patients with myocardial infarction. Available antiplatelet drugs have delayed onset and offset of action.〔 Since cangrelor’s effects are immediate and quickly reversed, it is a more desirable drug for elective treatment of stenotic coronary arteries, high risk acute coronary syndromes treated with immediate coronary stenting, and for bridging those surgery patients who require P2Y12 inhibition.〔 Current evidence regarding cangrelor therapy is limited by the lack studies assessing cangrelor administration in conjunction with either prasugrel or ticagrelor.〔 Recently , It's been approved for adult patients undergoing percutaneous coronary intervention (PCI). 〔(), FDA approves new antiplatelet drug used during heart procedure.〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cangrelor」の詳細全文を読む スポンサード リンク
|